Skip to content

logo

SEARCH icon
  • Investing News
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Financial
  • Health
  • MORE
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Industrials
    • Food & Beverage
Search

SEARCH FOR AN ARTICLE

  • Investing News
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Financial
  • Health
  • MORE
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Industrials
    • Food & Beverage

logo

icon

      HomeBiotech

      Biotech

      Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
      Biotech

      Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results

      November 16, 2026
      Mesoblast Showcased at ASX Premier Investor Day Event
      Biotech

      Mesoblast Showcased at ASX Premier Investor Day Event

      November 16, 2026
      HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
      Biotech

      HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®

      November 16, 2026
      Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
      Biotech

      Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights

      November 13, 2026
      Rakovina Therapeutics Expands Strategic Engagement with Renowned AI Drug Discovery Pioneer Dr. Artem Cherkasov
      Biotech

      Rakovina Therapeutics Expands Strategic Engagement with Renowned AI Drug Discovery Pioneer Dr. Artem Cherkasov

      November 12, 2026
      Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London
      Biotech

      Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London

      November 11, 2026
      Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies
      Biotech

      Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies

      November 11, 2026
      Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
      Biotech

      Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock

      November 11, 2026
      Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
      Biotech

      Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

      November 9, 2026
      IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
      Biotech

      IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses

      November 9, 2026
      « 1 2 3 4 … 212 »

       

      LATEST NEWS

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from Stock Street News.

      I want e-mail alerts, updates, and offers and agree to the StockStreetNews privacy policy.

      Market Jar Media Inc. © 2026